Organization (Industry)
ELI LILLY AND COMPANY
ClinicalTrials.gov lists ELI LILLY AND COMPANY as lead sponsor of 2,189 trials, counting the companies grouped under it. ELI LILLY AND COMPANY itself has 1,247 active development programs and 295 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 105 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 120 in 2026 and about 120 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (100 to 500), forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 1 trial is registered to start in 2027 or later.
Logo Eli Lilly and Company, converted to PNG by Huwmanbeing, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers ELI LILLY AND COMPANY and 13 companies grouped under it: 2,189 lead-sponsored trials (2,088 its own, 101 in the grouped companies) and 24 legal-entity registrations (3 its own, 21 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (13)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Avid Radiopharmaceuticals (United States) | 54 | 1 |
| Loxo Oncology, Inc. | 17 | 0 |
| Adverum Biotechnologies, Inc. | 11 | 0 |
| Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 5 | 0 |
| Prevail Therapeutics | 5 | 0 |
Showing 5 of 13 member companies.
Disease areas (437)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 505 |
| Diabetes Mellitus, Type 2 | 378 |
| Lung Neoplasms | 224 |
| Carcinoma, Non-Small-Cell Lung | 190 |
| Breast Neoplasms | 131 |
Showing 5 of 437 disease areas.
Trials by start year as sponsor or collaborator (32)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 105 |
| 2025 | 118 |
| 2024 | 92 |
| 2023 | 104 |
| 2022 | 90 |
| 2021 | 101 |
| 2020 | 129 |
| 2019 | 120 |
| 2018 | 103 |
| 2017 | 96 |
Showing 10 of 32 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 148 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 1,609 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1,247)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Eloralintide | Obesity | Phase 3 | 19 |
| Orforglipron | Obesity | Phase 3 | 22 |
| PEMBROLIZUMAB | Carcinoma, Non-Small-Cell Lung | Phase 3 | 16 |
| PEMBROLIZUMAB | Lung Neoplasms | Phase 3 | 16 |
| Anastrozole | Breast Neoplasms | Phase 3 | 9 |
Showing 5 of 1,247 active programs.
Approved assets (295)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| PEMETREXED | 108 |
| Duloxetine | 91 |
| INSULIN GLARGINE | 79 |
| TIRZEPATIDE | 75 |
| Insulin LISPRO | 73 |
Showing 5 of 295 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 58% hit target (n=687) | 40% on time (n=568) |
Journals published in (602)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 91 |
| Diabetes care | 83 |
| Lancet (London, England) | 61 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 57 |
| Circulation | 51 |
Showing 5 of 602 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 4,554 | 261 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 65,179,000,000 | 20,640,000,000 | 13,337,000,000 |
| 2024 | 45,043,000,000 | 10,590,000,000 | 10,991,000,000 |
| 2023 | 34,124,000,000 | 5,240,000,000 | 9,313,000,000 |
| 2022 | 28,541,400,000 | 6,244,800,000 | 7,190,800,000 |
| 2021 | 28,318,400,000 | 5,581,700,000 | 6,930,700,000 |
| 2020 | 24,539,800,000 | 6,193,700,000 | 5,976,300,000 |
| 2019 | 22,319,500,000 | 8,318,400,000 | 5,595,000,000 |
| 2018 | 21,493,300,000 | 3,232,000,000 | 5,051,200,000 |
| 2017 | 19,973,800,000 | -204,100,000 | 5,096,200,000 |
| 2016 | 21,222,100,000 | 2,737,600,000 | 5,310,300,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (32)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-20 | Debt financing | 8,940,000,000 | Sec extracted |
| 2026-05-08 | Debt financing | 8,981,442,500 | Edgar offerings |
| 2026-05-06 | Other financing | not disclosed | Edgar offerings |
| 2025-08-20 | Debt financing | 6,710,000,000 | Sec extracted |
| 2025-08-19 | Debt financing | 6,738,002,500 | Edgar offerings |
Showing 5 of 32 events.
FDA warning letters (3)
Shown in this order: most recent issue date first.
| Issue date | Letter |
|---|---|
| 2025-09-09 | eli-lilly-and-company-716462-09092025 |
| 2025-09-09 | eli-lilly-and-company-716475-09092025 |
| 2025-09-09 | eli-lilly-and-company-716485-09092025 |
FDA untitled letters (1)
| Issue date | Letter |
|---|---|
| 2022-01-19 | 155627 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 2 |
FDA recalls (5)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Sterile Diluent, HUMALOG U-100 (insulin lispro injection), HUMULIN R U-100 REGULAR (insulin human injection), Insulin Lispro Injection u-100, 10 mL, Use ONLY with Insulins listed on carton, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285. NDC: 0002-0800-01 | Class II | 2024-03-12 |
| Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe. Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285; Glucagon, NDC: 0002-8031-01 | Class I | 2021-09-24 |
| Trulicity (dulaglutide), 0.75 mg/0.5 mL, 4 Single-Dose Pens per box, Rx only, Eli Lilly and Company, Indianapolis, IN 46285, NDC 0002-1433-80 | Class II | 2021-08-19 |
| Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, NDC# 0002-7597-01 | Class II | 2021-06-29 |
| ERBITUX CETUXIMAB Injection, 200 mg/100 mL (2 mg/mL), 100 mL per single-use vial, Rx only, Manufactured by: ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, Branchburg, NJ 08876 USA. NDC: 66733-958-23 | Class III | 2018-11-08 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 9 | 2026-05-12 |
Manufacturing and distribution sites (6)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Eli Lilly and Company | Concord, US | FDA | |
| Eli Lilly and Company | Indianapolis, US | Health Canada | |
| Eli Lilly and Company Limited | Indianapolis, US | Health Canada | |
| Eli Lilly and Company | Indianapolis, US | EMA | |
| Eli Lilly and Company | Durham, US | FDA |
Showing 5 of 6 sites.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (352)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 36 |
| Roche (Switzerland) | Co sponsors trial with | 32 |
| Boehringer Ingelheim (Germany) | Co sponsors trial with | 18 |
| Astrazeneca Plc | Co sponsors trial with | 17 |
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 16 |
Showing 5 of 352 relationships.
Latest dated events (7,470)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 7,470 events.
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| ELI LILLY AND COMPANY | Certificate of waiver | Terminated |
| ELI LILLY & CO | Certificate of waiver | Terminated |
| ELI LILLY AND COMPANY | Certificate of waiver | Terminated |
Biomarker capability evidence (4,874)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
| ABR | Trial sponsor | Primary endpoint in a Phase 3 trial |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 4,874 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: biomarkers this organization publishes on.